Skip to main content
. 2017 Dec 18;8:892. doi: 10.3389/fphar.2017.00892

Table 4.

Reimbursement policy review in analyzed CEE countries.

Aspect required Bulgaria Croatia Czechia Estonia Hungary Latvia Lithuania Poland Romania Slovakia
Is there a positive reimbursement list available? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is there a negative reimbursement list available? No No No No Yes No No No Yes No
Are there co-payments for pharmaceuticals? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
How often are reimbursement decisions revised (periodic/ad hoc revisions)? Once a year Periodic several times a year Periodic once a 5 years but also ad hoc revision is possible Periodic every 3 months ad hoc revision Periodic, every 3 months ad hoc revision Periodic, every 2 months 1 year or ad hoc revision Periodic, every 3 months
Are risk sharing agreements (RSA) available in reimbursement decision making? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is a cap for patients for reimbursement expenses? Yes, currently in just some cases No No Yes No No No No Yes Yes, but only for vulnerable groups of patients